Clinical Trials Logo

Filter by:
NCT ID: NCT01373151 Completed - Clinical trials for Rheumatoid Arthritis

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.

NCT ID: NCT01372709 Completed - Clinical trials for Abdominal Aortic Aneurysm

TriVascular Post-Market Registry

Start date: May 2011
Phase:
Study type: Observational

This is a prospective observational post-market study of subjects receiving the Ovation™ or Ovation Prime™ Abdominal Stent Graft System ("Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market Study") in the treatment of abdominal aortic aneurysms (AAA). The Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market study is intended to expand the clinical knowledge base by collecting data on subjects treated with the Ovation™ or Ovation Prime™ Abdominal Stent Graft System in actual clinical practice following commercial approval.

NCT ID: NCT01371760 Completed - Multiple Sclerosis Clinical Trials

BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)

BRAVE-DREAMS
Start date: August 2012
Phase: N/A
Study type: Interventional

To assess in a double blinded randomized control trial (RCT) study design safety and effectiveness of balloon angioplasty of the main extracranial and extravertebral veins in multiple sclerosis (MS) associated to chronic cerebrospinal venous insufficiency (CCSVI). Mean follow-up 1 year. 5-8 Italian centres 360 relapsing remitting (RR) MS patients will be randomized, with expanded disability disease scale (EDSS) ranging 2-5.5, age 18-65.

NCT ID: NCT01371201 Completed - Clinical trials for Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

FIRSTMAPPP
Start date: December 22, 2011
Phase: Phase 2
Study type: Interventional

The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).

NCT ID: NCT01369420 Completed - Clinical trials for Pancreatic Adenocarcinoma

NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma. Safety will be reviewed by means of analysis of adverse events, including serious adverse events, laboratory data, physician exam findings, and vital signs.

NCT ID: NCT01369095 Completed - Depression Clinical Trials

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).

NCT ID: NCT01368744 Completed - Breast Neoplasms Clinical Trials

Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology

Start date: March 2010
Phase: N/A
Study type: Observational

The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to an extensive intraoperative frozen section protocol for Sentinel Lymph Nodes removed during standard Sentinel Lymph Node biopsy procedures from breast cancer subjects.

NCT ID: NCT01367665 Completed - Clinical trials for Basal Cell Carcinoma

STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Start date: July 1, 2011
Phase: Phase 2
Study type: Interventional

This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.

NCT ID: NCT01367470 Completed - Allergy Clinical Trials

Influence of Probiotic VSL#3 Administration on Metabolic and Immunological Profile of the Milk of Breastfeeding Mothers

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The newborn immune system is influenced by maternal immunity through both placenta and breastfeeding. There exists a close interaction between the mother and the baby during gestation and lactation. Maternal milk contains a number of factors that protect the newborn against infections including 1) cytokines and their receptors which are also thought to play a role in the protection against allergies; 2) oligosaccharides with low molecular weight and 3) probiotic bacteria that contribute to the development of the newborn immune system. Probiotics have a potent immunogenic activity as well as an immunoprotective potential in maternal milk after administration of probiotics during pregnancy and breastfeeding. In addition probiotics are supposed to play a role in the increased production of sphingomyelinase.

NCT ID: NCT01365546 Completed - Clinical trials for Prevent Bleeding in Major Surgery

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

WONDERS
Start date: June 2011
Phase: Phase 3
Study type: Interventional

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.